ANI Pharmaceuticals Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. 是一家多元化生物制药公司，通过开发、制造和营销品牌和仿制处方药产品（包括针对未满足医疗需求的疾病）为有需要的患者提供服务。该公司专注于通过其主要资产 Purified Cortrophin Gel 扩大其罕见病业务以及通过增强研发能力的仿制药业务，实现可持续增长。该公司拥有三家制药厂，其中两家位于明尼苏达州的 Baudette，一家位于新泽西州的 East Windsor，这些工厂共同能够生产口服固体剂量产品以及半固体、液体和外用药、管制物质和强效产品。该公司拥有约 118 种产品的商业组合，具有多种适应症和强大的产品线组合。

ANI Pharmaceuticals Inc简介



公司代码ANIP

公司名称ANI Pharmaceuticals Inc

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

员工数量897

证券类型Ordinary Share

年结日May 04

公司地址210 Main Street West

城市BAUDETTE

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编56623

电话12186343500

网址https://www.anipharmaceuticals.com/

公司代码ANIP

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

ANI Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-12.17%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-6.53%

Mr. Patrick D. Walsh

Independent Chairman of the Board

70.05K

-11.39%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

60.19K

-4.31%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

40.04K

-11.05%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

36.52K

-34.62%

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

26.96K

+19.17%

Mr. Matthew J. (Matt) Leonard

Independent Director

6.86K

-57.96%

名称

名称/职务

职务

持股

持股变动

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

411.22K

-12.17%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

84.02K

-6.53%

Mr. Patrick D. Walsh

Independent Chairman of the Board

70.05K

-11.39%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

60.19K

-4.31%

收入明细

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

业务USD

名称

营收

占比

Sales of generic pharmaceutical products

90.30M

0.00%

Sales of rare disease pharmaceutical products

81.65M

0.00%

Sales of Cortrophin Gel

81.65M

0.00%

Sales of branded pharmaceutical products

17.11M

0.00%

暂无数据

业务

地区

业务USD

名称

营收

占比

Sales of generic pharmaceutical products

90.30M

0.00%

Sales of rare disease pharmaceutical products

81.65M

0.00%

Sales of Cortrophin Gel

81.65M

0.00%

Sales of branded pharmaceutical products

17.11M

0.00%

股东统计

更新时间: 8月17日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.64%

The Vanguard Group, Inc.

5.71%

Meridian Venture Partners

4.55%

Millennium Management LLC

4.50%

Global Alpha Capital Management Ltd.

3.87%

其他

70.72%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.64%

The Vanguard Group, Inc.

5.71%

Meridian Venture Partners

4.55%

Millennium Management LLC

4.50%

Global Alpha Capital Management Ltd.

3.87%

其他

70.72%

股东类型

持股股东

占比

Investment Advisor

44.67%

Investment Advisor/Hedge Fund

21.80%

Hedge Fund

17.80%

Individual Investor

7.52%

Private Equity

4.55%

Research Firm

3.65%

Corporation

2.86%

Bank and Trust

1.67%

Pension Fund

1.63%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

501

21.40M

95.98%

-2.10M

2025Q2

505

24.45M

112.92%

-1.14M

2025Q1

511

24.19M

111.77%

-1.42M

2024Q4

489

23.75M

109.53%

-1.38M

2024Q3

473

23.30M

110.79%

+2.44M

2024Q2

446

19.77M

94.29%

-402.06K

2024Q1

424

18.72M

89.20%

-877.00K

2023Q4

409

18.10M

88.69%

-881.29K

2023Q3

396

18.38M

91.57%

-127.77K

2023Q2

370

17.73M

90.91%

+852.82K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.37M

10.64%

-68.37K

-2.80%

Jun 30, 2025

The Vanguard Group, Inc.

1.27M

5.71%

+95.32K

+8.09%

Jun 30, 2025

Meridian Venture Partners

1.01M

4.55%

-150.00K

-12.88%

Aug 21, 2025

Millennium Management LLC

1.00M

4.5%

-112.78K

-10.10%

Jun 30, 2025

Global Alpha Capital Management Ltd.

862.09K

3.87%

+126.50K

+17.20%

Jun 30, 2025

State Street Investment Management (US)

716.12K

3.21%

+1.55K

+0.22%

Jun 30, 2025

Deep Track Capital LP

700.00K

3.14%

--

Jun 30, 2025

Esjay L.L.C,

632.62K

2.84%

-200.00K

-24.02%

Mar 14, 2025

Citadel Advisors LLC

569.63K

2.56%

-153.70K

-21.25%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

553.89K

2.48%

-77.67K

-12.30%

Jun 30, 2025

持股ETF



更新时间: 11月2日周日

机构名称

占比

Invesco Pharmaceuticals ETF

2.7%

SPDR S&P Pharmaceuticals ETF

2.26%

Pacer US Small Cap Cash Cows Growth Leaders ETF

2.03%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.69%

Innovator IBD 50 Fund ETF

1.3%

Invesco Dorsey Wright Healthcare Momentum ETF

1.07%

Janus Henderson Small/Mid Cap Growth Alpha ETF

1.04%

Invesco S&P SmallCap Health Care ETF

1.01%

Innovator IBD Breakout Opportunities ETF

0.9%

First Trust Small Cap Growth AlphaDEX Fund

0.7%

Invesco Pharmaceuticals ETF

占比2.7%

SPDR S&P Pharmaceuticals ETF

占比2.26%

Pacer US Small Cap Cash Cows Growth Leaders ETF

占比2.03%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.69%

Innovator IBD 50 Fund ETF

占比1.3%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.07%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比1.04%

Invesco S&P SmallCap Health Care ETF

占比1.01%

Innovator IBD Breakout Opportunities ETF

占比0.9%

First Trust Small Cap Growth AlphaDEX Fund

占比0.7%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据